Skip to main content

6 Result(s)

within J. R. Infante Remove this filter

and

  1. No Access

    Article

    TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies

    This phase I trial evaluated the safety, pharmacokinetic profile, and antitumor activity of investigational oral TORC1/2 inhibitor TAK-228 plus paclitaxel, with/without trastuzumab, in patients with advanced s...

    Howard A. Burris III, C. D. Kurkjian, L. Hart… in Cancer Chemotherapy and Pharmacology (2017)

  2. No Access

    Article

    A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors

    Introduction This Phase Ib trial investigated the safety, tolerability, and recommended phase 2 dose for the pan-PI3K/mTOR inhibitor, GSK2126458 (GSK458), and trametinib combination when ...

    J. E. Grilley-Olson, P. L. Bedard, A. Fasolo, M. Cornfeld… in Investigational New Drugs (2016)

  3. Article

    Open Access

    Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies

    We assessed the maximum tolerated regimen (MTR) and dose-limiting toxicities of pazopanib and lapatinib in combination with weekly paclitaxel, and the effect of pazopanib and lapatinib on paclitaxel pharmacoki...

    A R Tan, A Dowlati, M N Stein, S F Jones, J R Infante… in British Journal of Cancer (2014)

    Download PDF (213 KB) View Article

  4. Article

    Open Access

    Intermittent dosing of axitinib combined with chemotherapy is supported by 18FLT-PET in gastrointestinal tumours

    We evaluated week-on/week-off axitinib dosing plus chemotherapy in patients with gastrointestinal tumours, including tumour thymidine uptake by fluorine-18 3′-deoxy-3′-fluorothymidine positron emission tomogra...

    C K Hoh, H A Burris III, J C Bendell, J Tarazi, B Rosbrook… in British Journal of Cancer (2014)

    Download PDF (584 KB) View Article

  5. No Access

    Article

    A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors

    Inhibition of kinesin spindle protein or Eg5 causes the formation of monoastral mitotic spindles, which leads to cell death. AZD4877 is a specific, potent inhibitor of Eg5.

    J. R. Infante, R. Kurzrock, J. Spratlin… in Cancer Chemotherapy and Pharmacology (2012)

  6. No Access

    Article

    Cerebrospinal fluid S-100 protein levels in neurological pathologies

    The aim of this paper was to evaluate S-100 concentration in cerebrospinal fluid (CSF) from patients with different neurological disorders, and in subjects with no proven neurological pathology, in order to st...

    J. R. Infante, A. Martínez, J. Ochoa… in Journal of Physiology and Biochemistry (2003)